Dexcom Inc banner

Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 69.83 USD -1.4% Market Closed
Market Cap: $27.2B

Net Margin

16%
Current
Improving
by 1.9%
vs 3-y average of 14%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16%
=
Net Income
$720.7m
/
Revenue
$4.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
16%
=
Net Income
$720.7m
/
Revenue
$4.5B

Peer Comparison

Country Company Market Cap Net
Margin
US
Dexcom Inc
NASDAQ:DXCM
27.2B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
189.6B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
171B USD
Loading...
US
Stryker Corp
NYSE:SYK
138.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
132.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
115.7B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58.8B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
45.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51.8B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
45.4B USD
Loading...
US
Resmed Inc
NYSE:RMD
39B USD
Loading...

Market Distribution

Higher than 78% of companies in the United States of America
Percentile
78th
Based on 15 072 companies
78th percentile
16%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Dexcom Inc
Glance View

Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.

DXCM Intrinsic Value
55.28 USD
Overvaluation 21%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
16%
=
Net Income
$720.7m
/
Revenue
$4.5B
What is Dexcom Inc's current Net Margin?

The current Net Margin for Dexcom Inc is 16%, which is above its 3-year median of 14%.

How has Net Margin changed over time?

Over the last 3 years, Dexcom Inc’s Net Margin has increased from 8.7% to 16%. During this period, it reached a low of 8.7% on Sep 30, 2022 and a high of 17.2% on Sep 30, 2024.

Back to Top